Table 3.
Treatment Discontinuations, Adverse Events, and Hematologic Abnormalities
| Antiretroviral Therapy, No. (%) |
|||
|---|---|---|---|
| Variable | No (n = 13) | Yes (n = 37) | Overall (n = 50) |
| Treatment discontinuation | 0 | 0 | 0 |
| Any adverse event | 13 (100) | 37 (100) | 50 (100) |
|
Common adverse event | |||
| Nasal congestion | 2(15) | 6(16) | 8(16) |
| Myalgia | 5(38) | 2 (5) | 7(14) |
| Headache | 1(8) | 4(11) | 5 (10) |
| Fatigue | 3 (23) | 2 (5) | 5 (10) |
| Diarrhea | 2 (15) | 2 (5) | 4 (8) |
| Nausea | 1 (8) | 2 (5) | 3 (6) |
| Constipation | 2 (15) | 1 (3) | 3 (6) |
| Urinarytract infection | 1 (8) | 2 (5) | 3 (6) |
| Serious adverse event | |||
| Pneumonia | 1 (8) | 0 | 1 (2) |
| Hematologic abnormalitya | |||
| Increased aspartate aminotransferase (201–400 U/L) | 0 | 1 (3) | 1 (2) |
| Increased blood creatinine phosphokinase (≥6130 U/L) | 0 | 1 (3) | 1 (2) |
| Decreased neutrophilcount (0.500–0.749 K/uL) | 1 (8) | 0 | 1 (2) |
| Elevated lipase (181–300 U/L) | 0 | 1 (3) | 1 (2) |
a
Percentage represents proportion of patients who had at least 1 laboratory value above the upper limit of normal.